Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
AssigneeTherabron Therapeutics, Inc.
InventorAprile L. Pilon-Clayton
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
Claims45
A method of treating rhinosinusitis caused by infection in the nasal passages of a patient comprising:
- administering recombinant human Clara Cell 10 kDa protein (“rhCC10”) at a concentration no greater than 2 milligrams/milliliter onto an intranasal mucosal membrane of a patient.
A method of slowing growth or regrowth of nasal polyps caused by infection in a patient comprising:
- administering rhCC10 at a concentration no greater than 2 milligrams/milliliter onto an intranasal mucosal membrane of a patient.
A method of treating chronic or recurrent bacterial sinus infection in a patient comprising:
- administering rhCC10 at a concentration no greater than 2 milligrams/milliliter onto an intranasal mucosal membrane of a patient.
A method of treating sinus pain caused by infection in a patient comprising:
- administering rhCC10 at a concentration no greater than 2 milligrams/milliliter onto an intranasal mucosal membrane of a patient.
A method of:
- treating rhinosinusitis caused by infection, slowing growth or regrowth of nasal polyps caused by infection, treating chronic or recurrent bacterial sinus infection, or treating sinus pain caused by infection in a patient comprising administering rhCC10 via a squeeze spray bottle, pump action spray device, metered dose nasal actuator, syringe-type instillation device, nasal swab applicator, or “Neti pot” lavage to the surfaces of the nasal passages.
Dependencies are inferred from the claim text.